Corporate Profile

NexImmune, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, developing T cell immunotherapies through its proprietary Artificial Immune Modulation (AIM) technology. AIM nanoparticles are designed to act as synthetic dendritic cells, delivering immune-specific signals that can activate or suppress targeted T cell responses. The platform supports both adoptive cell therapy and direct injectable (AIM INJ) approaches across oncology, autoimmune disease, and infectious disease.

The company advanced NEXI-001 and NEXI-002 in Phase 1/2 studies for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplant and for relapsed/refractory multiple myeloma, respectively. NexImmune has reported clinical and preclinical data supporting antigen-specific T cell activity, and continues to focus resources on its AIM INJ nanoparticle platform. Additional program history, scientific publications, and pipeline details are available on the corporate pipeline page and in the press release archive on this site.

What You Will Find on This Site

This investor relations hub is maintained for shareholders, prospective investors, and equity research analysts who follow NexImmune. Use the sections below and the investor menu to review recent news, quarterly and annual reports filed with the U.S. Securities and Exchange Commission, stock quote and historical price data, conference participation, and corporate governance materials including board composition and committee charters. For a focused explanation of the AIM platform written for investors, see the AIM Technology Guide.

Press releases and SEC filings are posted as they are issued. For email notification when new materials are published, visit Email Alerts. For direct inquiries to the investor relations team, use the contact information on the Investor Contact page.

Recent Strategic Updates

In 2023, NexImmune announced a workforce alignment intended to extend cash runway while prioritizing development of the AIM INJ injectable platform in oncology and autoimmune indications. The company also extended a research collaboration with Yale University and JDRF focused on type 1 diabetes applications of its technology.

In early 2024, NexImmune completed a registered direct offering priced at-the-market under Nasdaq rules, providing additional capital to support ongoing operations and platform development. Full details appear in the February 2024 press releases in the Latest Releases section below and in related filings under Financials and Filings.